[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100447248":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":19,"responsibleParty":35,"collaborators":7,"id":37,"slug":7,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":41,"acronym":7,"eligibilityCriteria":42,"healthyVolunteers":38,"sex":43,"minAge":44,"maxAge":7,"enrollmentInfo":45,"targetDuration":7,"studyType":48,"phases":7,"briefSummary":49,"conditions":50,"keywords":7,"overallStatus":22,"whyStopped":7,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},{"fullName":5,"class":6},"Federation Francophone de Cancerologie Digestive","OTHER",null,[9],{"name":10,"affiliation":11,"role":12},"Rosine GUIMBAUD, PhD.MD","Fédération francophone de Cancérologie digestive","PRINCIPAL_INVESTIGATOR",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"ROSINE GUIMBAUD, PhD.MD","CONTACT","+33 (0)5 61 32 21 42","guimbaud.r@chu-toulouse.fr",[20],{"facility":21,"status":22,"city":23,"state":7,"zip":24,"country":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"CHU -hopital Rangeuil","RECRUITING","Toulouse","31059","France",{"type":27,"coordinates":28},"Point",[29,30],1.44367,43.60426,{"lat":30,"lon":29},[33],{"name":34,"role":16,"phone":17,"phoneExt":7,"email":18},"Rosine GUIMBAUD, PhD MD",{"type":36,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100447248",false,"NCT05103969","Cohort of Tumors With POLE\u002FD1 Mutation","Multicenter Prospective Cohort of Tumors With Pole\u002FD1 Mutation","Inclusion Criteria:\n\n* Any tumor presenting a variant of the exonuclease domain of POLE (exons 9 to 14) classified as pathogenic by the project working group, including: the 4 hotspots of mutations described (codons 286 (P286R\u002FH\u002FL), 411 (V411L), 459 (S459F), 424 (L424\u002FV\u002FI), (2).\n* Any tumor presenting a variant of the exonuclease domain of PolD1 (exons 8-12), classified as pathogenic by the project working group, including : C319Y(10).\n\nDiagnosis made from the date of launch of the cohort and in the previous year\n\n-Age ≥ 18 years\n\nExclusion Criteria:\n\n* Tumor without POLE or POLD1 mutation\n* Tumor with POLE mutation identified in research studies retrospective research\n* Opposition of the patient to the registration of his data in the cohort","ALL","18 Years",{"count":46,"type":47},100,"ESTIMATED","OBSERVATIONAL","Primary objective of this study is to identify and describe the clinico-biological and molecular characteristics of tumors with somatic POLE (Polymerase ɛ)\u002FPOLD1 mutation identified by molecular biology platforms for all stages and primary sites combined",[51,52,53],"Tumors","POLE Exonuclease Domain Mutation","POLD1 Gene Mutation","2024-07-05",{"date":56,"type":57},"2024-07-08","ACTUAL",{"date":59,"type":57},"2021-10-05",{"date":61,"type":47},"2025-10-06",{"name":5,"class":6},1]